Feasibility of Automated Insulin Delivery With an Interoperable Algorithm Using an Alternative Insulin Pump
Key facts
- Who runs it
- Imperial College London
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 1 person enrolled
- Started
- 1 Apr 2022
- Ended
- 31 Aug 2025
- Type of study
- Interventional
- Treatments tested
- InControl
- Record updated
- 3 September 2025
- Why it stopped
- Study device not available
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Aged 18 years of age or older
- Type 1 diabetes confirmed on the basis of clinical features
- Type 1 diabetes for greater than 1 year
- On an intensified insulin regimen with multiple dose injection or insulin pump for > 3 months
- HbA1c >7.5% (58mmol/mol) (or %TIR 3.9-10mmol/L <52% for participants already using a continuous glucose sensor)
Who cannot take part
- Have active malignancy or under investigation for malignancy
- Severe visual impairment
- Total daily insulin dose greater than 100 units
- Weight greater than 140kg
- Pregnant or planning pregnancy
- Reduced manual dexterity
- Use of any automated insulin delivery system
- Unable to participate due to other factors, as assessed by the Chief Investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical study assesses the feasibility of implementing the inControl automated insulin delivery algorithm with Dexcom continuous glucose monitoring and a compatible insulin pump in adults with type 1 diabetes. It additionally provides pilot efficacy outcomes for interoperable automated insulin delivery.
The group in the trial
- Automated Insulin DeliveryTreatment being tested
The components of the automated insulin delivery system are the Dexcom G6 continuous glucose monitor (CGM), the InControl algorithm and an insulin pump (Ypsomed Ypsopump). The Dexcom G6 continuous glucose monitoring device is an approved device and is licensed to be used to inform insulin dosing decisions without confirmation. The algorithm (inControl 1.0) is approved when used embedded in the Tandem X2 insulin pump. We are using the algorithm for its intended purpose but are implementing it in a smartphone app to be installed in a compatible smartphone (Android). We are additionally assessing incremental benefit with the next software version of the algorithm. This will be the first time this updated software has been assessed in people with type 1 diabetes. The compatible insulin pump is a continuous subcutaneous insulin infusion device and is being used in line with its intended purpose, according to the manufacturer's instructions (YpsoMed Ypsopump).
Treatment: InControl
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 3 September 2025